Cargando…

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis

Background: Although with the application of etanercept biosimilars in the field of rheumatoid arthritis, the evidences of their efficacy, safety, and immunogenicity are still limited. We conducted this meta-analysis to evaluate the efficacy, safety and immunogenicity of etanercept biosimilars for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Rui, Yuan, Tao, Wang, Hui, Zhao, Jianglin, Shi, Liya, Li, Quankai, Zhu, Chunmei, Su, Na, Zhang, Shengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979087/ https://www.ncbi.nlm.nih.gov/pubmed/36874005 http://dx.doi.org/10.3389/fphar.2023.1089272

Ejemplares similares

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
por: Wei, Qige, et al.
Publicado: (2023)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
por: Xu, Xinyi, et al.
Publicado: (2022)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
por: Jaworski, Janusz, et al.
Publicado: (2019)

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
por: Matucci-Cerinic, Marco, et al.
Publicado: (2018)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
por: Yamanaka, Hisashi, et al.
Publicado: (2019)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Safety of etanercept in elderly subjects with rheumatoid arthritis
por: Lurati, Alfredomaria, et al.
Publicado: (2010)

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
por: Park, Min-Chan, et al.
Publicado: (2019)

Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali(®)) Versus Etanercept (Enbrel(®)) - Findings from a Nurse Survey in Europe
por: Thakur, Kunal, et al.
Publicado: (2016)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Etanercept Inhibits B Cell Differentiation by Regulating TNFRII/TRAF2/NF-κB Signaling Pathway in Rheumatoid Arthritis
por: Cai, Xiao-Yu, et al.
Publicado: (2020)

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
por: Ascef, Bruna de Oliveira, et al.
Publicado: (2023)

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
por: Zhang, Hong, et al.
Publicado: (2021)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
por: Talotta, Rossella, et al.
Publicado: (2017)

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA(®) in Chinese healthy male subjects
por: Cao, Guoying, et al.
Publicado: (2023)

Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis, Elizabeth Mary, et al.
Publicado: (2014)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020)

Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study
por: Wu, Qingjun, et al.
Publicado: (2020)

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
por: Emery, Paul, et al.
Publicado: (2017)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
por: Combe, B, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_gi5i89t69kdqf1lghbro8pscfj